Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: <scp>FLEX</scp> ‐ <scp>SEMA</scp> 2.4 mg, an Italian real‐world study
This real-world analysis provides valuable insights into the use of semaglutide in routine clinical practice, confirming a favourable efficacy profile with flexible dosing patterns.
Authors
- Stefano Terzoni (ORCID: https://orcid.org/0000-0002-0716-5663)
- Sara Alberti
- Simone Pampanelli (ORCID: https://orcid.org/0000-0003-0255-4210)
- Chiara Di Loreto (ORCID: https://orcid.org/0009-0003-4834-5761)
- Alessio Mazzieri (ORCID: https://orcid.org/0009-0006-0102-2430)
- Paola Pantanetti (ORCID: https://orcid.org/0000-0001-8560-6631)
- Nicoletta Benenati (ORCID: https://orcid.org/0000-0003-1190-7962)
- Giovanni Cangelosi (ORCID: https://orcid.org/0000-0002-8523-6906)
- Sara Migliarelli
- MARIACLAUDIA CERRAI CERONI
- Cristina Badiali
- Maria Grazia Castagna
Institutions
- University of Siena (IT)
- University of Milan (IT)
- Ferring Pharmaceuticals (Switzerland) (CH)
- University of Perugia (IT)
- Ospedale Santa Maria (IT)
- Ospedale San Donato (IT)
- ASM Terni (Italy) (IT)
- University for Foreigners Perugia (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1111/dom.70538
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00